Ignacio Pino

Drug Discovery

Ignacio Pino is the co-founder and Chief Operating Officer of CDI Labs, where he has led the development of cutting-edge technology platforms such as Hu-Prot to advance pharmaceutical research and basic science discovery. Under his leadership, CDI Labs has grown into a recognized player in Puerto Rico’s biotech sector, bridging academic innovation with applications in antibodies, biomarkers, and drug discovery.

With extensive experience in biotechnology operations, Ignacio brings a unique combination of scientific expertise, strategic vision, and entrepreneurial execution. He has a proven record of translating early-stage technologies into scalable solutions that serve both industry and academia, positioning BioVergence to accelerate collaboration across ecosystems and drive meaningful impact at the intersection of science and commercialization.

AI-native capital formation for scientific assets

Address

750 Main Street, Cambridge, MA 02139, USA

Poststrasse 30, 6300 Zug, Switzerland

©2026 BioVergence All Rights Reserved

AI-native capital formation for scientific assets

Address

750 Main Street, Cambridge, MA 02139, USA

Poststrasse 30, 6300 Zug, Switzerland

©2026 BioVergence All Rights Reserved

Ignacio Pino

Drug Discovery

Ignacio Pino is the co-founder and Chief Operating Officer of CDI Labs, where he has led the development of cutting-edge technology platforms such as Hu-Prot to advance pharmaceutical research and basic science discovery. Under his leadership, CDI Labs has grown into a recognized player in Puerto Rico’s biotech sector, bridging academic innovation with applications in antibodies, biomarkers, and drug discovery.

With extensive experience in biotechnology operations, Ignacio brings a unique combination of scientific expertise, strategic vision, and entrepreneurial execution. He has a proven record of translating early-stage technologies into scalable solutions that serve both industry and academia, positioning BioVergence to accelerate collaboration across ecosystems and drive meaningful impact at the intersection of science and commercialization.

AI-native capital formation for scientific assets

Address

750 Main Street, Cambridge, MA 02139, USA

Poststrasse 30, 6300 Zug, Switzerland

©2026 BioVergence All Rights Reserved